R-CHOP + acalabrutinib

DRUG2 trials

Sponsors

University Hospital Southampton NHS Foundation Trust

Conditions

Diffuse Large B Cell LymphomaNon Hodgkin Lymphoma

Phase 1

A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

CompletedNCT03571308

University Hospital Southampton NHS Foundation TrustNon Hodgkin Lymphoma

Start: 2017-06-02End: 2023-08-31Updated: 2023-09-28

Phase 2

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruitingNCT04546620

University Hospital Southampton NHS Foundation TrustDiffuse Large B Cell Lymphoma

Start: 2021-10-19End: 2028-05-01Target: 453Updated: 2026-04-30

Related Papers

Randomised Phase II study of acalabrutinib in combination with R-CHOP treatment for diffuse large B-cell lymphoma confirms safety and unimpaired treatment delivery

Blood2025-11-03

REMODL‐A: A RANDOMISED PHASE II EVALUATION OF MOLECULAR GUIDED THERAPY FOR DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) WITH ACALABRUTINIB — ONGOING TRIAL

Hematological Oncology2023-06-012 citations

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Blood2022-11-154 citations

A phase 2, multicentre, open‐label trial (<scp>ACE‐LY</scp>‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

British Journal of Haematology2022-07-2128 citations

ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)

Hematological Oncology2019-06-014 citations